FR22C1033I1 - Use of dihydroimidazolones for the treatment of dogs - Google Patents

Use of dihydroimidazolones for the treatment of dogs

Info

Publication number: FR22C1033I1
Authority: FR; France
Prior art keywords: dihydroimidazolones; dogs; treatment
Prior art date: 2002-10-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR22C1033C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Boehringer Ingelheim Vetmedica GmbH

Original Assignee

Boehringer Ingelheim Vetmedica GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-10

Filing date

2022-06-30

Publication date

2022-09-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32094042&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR22C1033(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2022-06-30 Application filed by Boehringer Ingelheim Vetmedica GmbH filed Critical Boehringer Ingelheim Vetmedica GmbH

2022-09-09 Publication of FR22C1033I1 publication Critical patent/FR22C1033I1/en

Status Active legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

FR22C1033C 2002-10-10 2022-06-30 Use of dihydroimidazolones for the treatment of dogs Active FR22C1033I1 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US41759002P	2002-10-10	2002-10-10
PCT/EP2003/011212 WO2004032938A1 (en)	2002-10-10	2003-10-09	Use of dihydroimidazolones for the treatment of epilepsy in dogs
EP08167818A EP2036563A1 (en)	2002-10-10	2003-10-09	Use of dihydroimidazolones for the treatment of behavioural abnormalities in dogs
EP03757945A EP1553952B1 (en)	2002-10-10	2003-10-09	Use of dihydroimidazolones for the treatment of epilepsy in dogs

Publications (1)

Publication Number	Publication Date
FR22C1033I1 true FR22C1033I1 (en)	2022-09-09

Family

ID=32094042

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
FR13C0044C Active FR13C0044I2 (en)	2002-10-10	2013-07-24	USE OF DIHYDROIMIDAZOLONES FOR THE TREATMENT OF CANINE EPILEPSY
FR22C1033C Active FR22C1033I1 (en)	2002-10-10	2022-06-30	Use of dihydroimidazolones for the treatment of dogs

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
FR13C0044C Active FR13C0044I2 (en)	2002-10-10	2013-07-24	USE OF DIHYDROIMIDAZOLONES FOR THE TREATMENT OF CANINE EPILEPSY

Country Status (27)

Country	Link
US (5)	US20050070537A1 (en)
EP (3)	EP2845594B1 (en)
JP (4)	JP4694202B2 (en)
KR (2)	KR20110063843A (en)
CN (2)	CN101890019A (en)
AR (1)	AR041573A1 (en)
AT (1)	ATE418337T1 (en)
AU (2)	AU2003273978B2 (en)
BE (1)	BE2013C046I2 (en)
BR (1)	BR0315225A (en)
CA (2)	CA2727722C (en)
CY (3)	CY1109961T1 (en)
DE (1)	DE60325496D1 (en)
DK (2)	DK1553952T3 (en)
ES (2)	ES2316808T3 (en)
FR (2)	FR13C0044I2 (en)
HR (3)	HRP20050322B1 (en)
HU (2)	HUS1300035I1 (en)
LU (1)	LU92238I2 (en)
MX (1)	MXPA05003663A (en)
NZ (1)	NZ539864A (en)
PL (2)	PL238776B1 (en)
PT (2)	PT2845594T (en)
SI (2)	SI2845594T1 (en)
TW (2)	TWI324067B (en)
WO (1)	WO2004032938A1 (en)
ZA (1)	ZA200502245B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050070537A1 (en)	2002-10-10	2005-03-31	Chris Rundfeldt	Use of dihydroimidazolones for the treatment of dogs
US20050032863A1 (en) *	2003-07-11	2005-02-10	Barbara Langen	Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor
BR112014003061A2 (en)	2011-08-12	2017-02-21	Boehringer Ingelheim Vetmedica Gmbh	masked flavor pharmaceutical composition
JP6193613B2 (en) *	2013-05-10	2017-09-06	学校法人麻布獣医学園	Epilepsy seizure monitoring system and method
US9820988B2 (en)	2014-03-24	2017-11-21	Boehringer Ingelheim Vetmedica Gmbh	Treatment of epileptic disorders in feline animals
ES2715050T3 (en)	2014-05-28	2019-05-31	Toa Eiyo Ltd	Tropane derivatives substituted
CA2961410C (en)	2014-09-16	2023-07-11	India Globalization Capital, Inc.	Cannabinoid composition and method for treating pain
EP3247359A4 (en)	2015-01-25	2018-08-08	India Globalization Capital, Inc.	Composition and method for treating seizure disorders
WO2017027651A1 (en)	2015-08-12	2017-02-16	India Globalization Capital, Inc.	Method and composition for treating cachexia and eating disorders
CA3027862A1 (en)	2016-06-15	2017-12-21	India Globalization Capital, Inc.	Method and composition for treating seizure disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4044021A (en)	1971-10-21	1977-08-23	American Cyanamid Company	Tetrasubstituted imidazolidine diuretics useful in the treatment of hyperaldosteronism
US3932452A (en)	1975-02-07	1976-01-13	Morton-Norwich Products, Inc.	1-Arylmethyl-2-imidazolidinones
US5869481A (en)	1995-09-05	1999-02-09	Arzneitmittelwerk Dresden G.M.B.H.	Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making
DE19532668A1 (en)	1995-09-05	1997-03-06	Dresden Arzneimittel	Novel, anticonvulsant 1-ar (alk) yl-imidazolin-2-ones which contain a disubstituted amine radical in the 4-position, and process for their preparation
DE19721580A1 (en) *	1997-05-23	1998-11-26	Dresden Arzneimittel	Use of 1-ar (alk) yl-imidazolin-2-one for the treatment of anxiety and tension
WO1999000346A1 (en)	1997-06-26	1999-01-07	Board Of Regents, The University Of Texas System	Synthesis of dihydrohonokiol compositions
JP4669095B2 (en)	1999-07-19	2011-04-13	太陽化学株式会社	Composition for suppressing behavioral problems in pets
IL163863A0 (en)	2002-03-07	2005-12-18	Boehringer Sohn Ingelheim	Form of presentation for3-Ä(2-äÄ4-(hexyloxycarbonylamino-imino-methyl)-phenylaminoÜmethylü-1-methyl-1H-benzimidaz
US20050070537A1 (en) *	2002-10-10	2005-03-31	Chris Rundfeldt	Use of dihydroimidazolones for the treatment of dogs
DE10339862A1 (en)	2003-08-29	2005-03-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	New crystalline forms of ethyl 3-(N-(2-(4-(hexyloxycarbonylamidino)phenylaminomethyl)-1-methyl-1H-benzimidazole-5-carbonyl)-N-(2-pyridyl)amino)propionate methanesulfonate used for post-operative prophylaxis of deep vein thrombosis
BR112014003061A2 (en)	2011-08-12	2017-02-21	Boehringer Ingelheim Vetmedica Gmbh	masked flavor pharmaceutical composition
US9820988B2 (en)	2014-03-24	2017-11-21	Boehringer Ingelheim Vetmedica Gmbh	Treatment of epileptic disorders in feline animals

2003
- 2003-10-06 US US10/680,459 patent/US20050070537A1/en not_active Abandoned
- 2003-10-08 TW TW092127976A patent/TWI324067B/en not_active IP Right Cessation
- 2003-10-08 TW TW098142077A patent/TWI424849B/en not_active IP Right Cessation
- 2003-10-09 KR KR1020117009632A patent/KR20110063843A/en not_active Ceased
- 2003-10-09 NZ NZ539864A patent/NZ539864A/en not_active IP Right Cessation
- 2003-10-09 PT PT141910844T patent/PT2845594T/en unknown
- 2003-10-09 AT AT03757945T patent/ATE418337T1/en active
- 2003-10-09 JP JP2004542480A patent/JP4694202B2/en not_active Expired - Lifetime
- 2003-10-09 PL PL397320A patent/PL238776B1/en unknown
- 2003-10-09 ES ES03757945T patent/ES2316808T3/en not_active Expired - Lifetime
- 2003-10-09 CN CN2010101440231A patent/CN101890019A/en active Pending
- 2003-10-09 HR HRP20050322AA patent/HRP20050322B1/en not_active IP Right Cessation
- 2003-10-09 BR BR0315225-1A patent/BR0315225A/en not_active Application Discontinuation
- 2003-10-09 DK DK03757945T patent/DK1553952T3/en active
- 2003-10-09 DE DE60325496T patent/DE60325496D1/en not_active Expired - Lifetime
- 2003-10-09 WO PCT/EP2003/011212 patent/WO2004032938A1/en not_active Ceased
- 2003-10-09 AU AU2003273978A patent/AU2003273978B2/en not_active Expired
- 2003-10-09 HR HRP20090667AA patent/HRP20090667B1/en not_active IP Right Cessation
- 2003-10-09 EP EP14191084.4A patent/EP2845594B1/en not_active Expired - Lifetime
- 2003-10-09 EP EP08167818A patent/EP2036563A1/en not_active Ceased
- 2003-10-09 CA CA2727722A patent/CA2727722C/en not_active Expired - Lifetime
- 2003-10-09 PT PT03757945T patent/PT1553952E/en unknown
- 2003-10-09 HR HRP20200207AA patent/HRP20200207A2/en not_active Application Discontinuation
- 2003-10-09 AR ARP030103685A patent/AR041573A1/en unknown
- 2003-10-09 CA CA2501772A patent/CA2501772C/en not_active Expired - Lifetime
- 2003-10-09 MX MXPA05003663A patent/MXPA05003663A/en active IP Right Grant
- 2003-10-09 SI SI200332622T patent/SI2845594T1/en unknown
- 2003-10-09 SI SI200331504T patent/SI1553952T1/en unknown
- 2003-10-09 CN CN2003801057558A patent/CN1726040B/en not_active Expired - Lifetime
- 2003-10-09 KR KR1020057006150A patent/KR101110587B1/en not_active Expired - Lifetime
- 2003-10-09 EP EP03757945A patent/EP1553952B1/en not_active Expired - Lifetime
- 2003-10-09 DK DK14191084.4T patent/DK2845594T3/en active
- 2003-10-09 ES ES14191084T patent/ES2908453T3/en not_active Expired - Lifetime
- 2003-10-09 PL PL374603A patent/PL214702B1/en unknown
2005
- 2005-03-17 ZA ZA2005/02245A patent/ZA200502245B/en unknown
2007
- 2007-07-18 US US11/879,708 patent/US8859540B2/en active Active
2009
- 2009-03-20 CY CY20091100314T patent/CY1109961T1/en unknown
- 2009-10-12 AU AU2009225322A patent/AU2009225322A1/en not_active Abandoned
2010
- 2010-12-28 JP JP2010293113A patent/JP2011068685A/en not_active Withdrawn
2012
- 2012-09-14 US US13/616,440 patent/US8962617B2/en not_active Expired - Lifetime
2013
- 2013-07-03 LU LU92238C patent/LU92238I2/en unknown
- 2013-07-03 BE BE2013C046C patent/BE2013C046I2/fr unknown
- 2013-07-11 CY CY2013031C patent/CY2013031I1/en unknown
- 2013-07-24 HU HUS1300035C patent/HUS1300035I1/en unknown
- 2013-07-24 FR FR13C0044C patent/FR13C0044I2/en active Active
2014
- 2014-02-14 JP JP2014026704A patent/JP6249812B2/en not_active Expired - Lifetime
- 2014-11-17 US US14/542,888 patent/US9469611B2/en not_active Expired - Fee Related
2016
- 2016-02-29 JP JP2016038151A patent/JP2016104817A/en not_active Withdrawn
- 2016-08-30 US US15/251,022 patent/US20160367562A1/en not_active Abandoned
2022
- 2022-03-31 CY CY20221100250T patent/CY1125103T1/en unknown
- 2022-06-30 FR FR22C1033C patent/FR22C1033I1/en active Active
- 2022-07-28 HU HUS2200036C patent/HUS2200036I1/en unknown

Also Published As

Publication number	Publication date
CN1726040A (en)	2006-01-25
DK1553952T3 (en)	2009-04-20
BE2013C046I2 (en)	2022-08-09
US20150072983A1 (en)	2015-03-12
TW200503726A (en)	2005-02-01
DE60325496D1 (en)	2009-02-05
CA2727722A1 (en)	2004-04-22
KR101110587B1 (en)	2012-02-15
US8859540B2 (en)	2014-10-14
CA2727722C (en)	2013-05-28
AR041573A1 (en)	2005-05-18
ZA200502245B (en)	2005-11-30
ES2908453T3 (en)	2022-04-29
TWI324067B (en)	2010-05-01
KR20110063843A (en)	2011-06-14
EP1553952A1 (en)	2005-07-20
EP2036563A1 (en)	2009-03-18
ATE418337T1 (en)	2009-01-15
US20080027057A1 (en)	2008-01-31
FR13C0044I2 (en)	2014-03-07
CN1726040B (en)	2010-05-12
HUS2200036I1 (en)	2022-08-28
SI2845594T1 (en)	2022-04-29
TW201010706A (en)	2010-03-16
PL214702B1 (en)	2013-09-30
JP2016104817A (en)	2016-06-09
JP4694202B2 (en)	2011-06-08
BR0315225A (en)	2005-08-23
NZ539864A (en)	2007-11-30
HRP20200207A2 (en)	2020-07-24
MXPA05003663A (en)	2005-06-08
HRP20050322A2 (en)	2006-05-31
PT2845594T (en)	2022-03-09
CA2501772C (en)	2011-08-23
US20050070537A1 (en)	2005-03-31
CY2013031I2 (en)	2015-11-04
WO2004032938A1 (en)	2004-04-22
ES2316808T3 (en)	2009-04-16
CY1109961T1 (en)	2014-09-10
CY2013031I1 (en)	2015-11-04
US20160367562A1 (en)	2016-12-22
JP6249812B2 (en)	2017-12-20
PL397320A1 (en)	2012-02-13
AU2003273978A1 (en)	2004-05-04
HRP20090667B1 (en)	2021-06-11
LU92238I2 (en)	2013-09-03
SI1553952T1 (en)	2009-04-30
JP2006503873A (en)	2006-02-02
FR13C0044I1 (en)	2013-08-30
JP2014080449A (en)	2014-05-08
PL238776B1 (en)	2021-10-04
EP2845594A1 (en)	2015-03-11
HRP20090667A2 (en)	2010-07-31
EP1553952B1 (en)	2008-12-24
JP2011068685A (en)	2011-04-07
US8962617B2 (en)	2015-02-24
CN101890019A (en)	2010-11-24
US9469611B2 (en)	2016-10-18
TWI424849B (en)	2014-02-01
CA2501772A1 (en)	2004-04-22
US20130065898A1 (en)	2013-03-14
PL374603A1 (en)	2005-10-31
DK2845594T3 (en)	2022-03-07
HUS1300035I1 (en)	2017-10-30
HK1085920A1 (en)	2006-09-08
CY1125103T1 (en)	2023-01-05
EP2845594B1 (en)	2022-02-23
AU2009225322A1 (en)	2009-11-05
KR20050056237A (en)	2005-06-14
LU92238I9 (en)	2019-01-09
PT1553952E (en)	2009-02-10
HRP20050322B1 (en)	2013-12-06
AU2003273978B2 (en)	2009-07-23

Publication	Publication Date	Title
FR22C1033I1 (en)	2022-09-09	Use of dihydroimidazolones for the treatment of dogs
EP1501489A4 (en)	2007-11-21	POLYTHERAPY FOR THE TREATMENT OF CANCER
EP1587502A4 (en)	2011-05-25	DRESSING FOR INJURY
EP1534074A4 (en)	2008-01-09	POLYTHERAPY FOR THE TREATMENT OF OBESITY
EP1951272A4 (en)	2010-01-27	USE OF LACTOBACILLUS FOR THE TREATMENT OF VIRAL INFECTIONS
NO20021526L (en)	2002-09-30	Sewage treatment device
EP1601251A4 (en)	2007-03-28	COMPOUNDS FOR THE TREATMENT OF TABOLIC M DISORDERS
DE60204951D1 (en)	2005-08-11	CCR5 ANTAGONISTS USE FOR THE TREATMENT OF AIDS
EP1485109A4 (en)	2009-07-29	VASCULAR TREATMENT
MA27395A1 (en)	2005-06-01	USE OF PREBIOTICS FOR THE TREATMENT AND PREVENTION OF HYPER-GLYCEMIC SYNDROMES
EP1581243A4 (en)	2008-01-02	ORAL LACTOFERRINE FOR THE TREATMENT OF SEPSIES
EP1750513A4 (en)	2009-07-22	USE OF GPCR54 LIGANDS FOR THE TREATMENT OF INFERTILITY
EP1359885A4 (en)	2005-03-16	INHIBITORS OF NOS FOR THE TREATMENT OF WRINKLES
FR2860154B1 (en)	2006-02-03	COMPOSITION FOR THE TREATMENT OF MALE BREATH
EP1172113A4 (en)	2004-06-30	REMEDIES FOR THE TREATMENT OF AUTOMATIC NEUROPATHIES
FR2868307B1 (en)	2008-03-14	USE OF BETA-ENDORPHINE FOR THE TREATMENT OF WRINKLES
FR2834887B1 (en)	2007-06-15	USE OF ARTEMIA EXTRACT FOR THE TREATMENT OF OLD SKIN
ATE391507T1 (en)	2008-04-15	S-METHYL-DIHYDRO-ZIPRASIDONE FOR THE TREATMENT OF SCHIZOPHRENIA
EP1638573A4 (en)	2009-12-02	USE OF SELECTIVE TYPE 2 CYCLOOXYGENASE INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS
FR2849599B1 (en)	2006-12-29	USE OF KYNURENINE-3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES
EP1804805A4 (en)	2008-08-13	USE OF AROMATASE INHIBITORS FOR THE TREATMENT OF ECTOPIC PREGNANCY
FR2832429B1 (en)	2004-01-09	IMPROVED WORKPIECE DEVICE FOR ELECTROLYTIC TREATMENT
FR2843015B1 (en)	2005-06-10	IMPLANT FOR THE TREATMENT OF PRESBYOPIA
FI20021374A7 (en)	2004-01-13	Wastewater treatment unit
IT1316554B1 (en)	2003-04-22	DEVICE FOR THE TREATMENT OF WET WASTE.